Lion Point Capital »

Royalty Pharma shares owned by Lion Point Capital

Quarter-by-quarter ownership of Royalty Pharma (RPRX) shares owned by Lion Point Capital from 13F filings

Historical chart of Lion Point Capital investment in Royalty Pharma

Tip: Access up to 7 years of quarterly data

All positions including Royalty Pharma held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Royalty Pharma by Lion Point Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $755k 21k 35.28

More positions owned by Lion Point Capital

Mineralys Therapeutics (MLYS)
Milestone Pharmaceuticals (MIST)
Fennec Pharmaceuticals (FENC)
Jasper Therapeutics Com New (JSPR)
Avadel Pharmaceuticals Com Shs (AVDL)
Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Insmed Com Par $.01 (INSM)
Ardelyx (ARDX)
Benitec Biopharma Com New (BNTC)
Syndax Pharmaceuticals (SNDX)
Royalty Pharma Shs Class A (RPRX)
Disc Medicine (IRON)
Bridgebio Pharma (BBIO)
Geron Corporation (GERN)
Arcutis Biotherapeutics (ARQT)

View all positions for Lion Point Capital

Top funds holding Royalty Pharma

Morgan Stanley
FMR
Capital Research and Management Company - Division 3
BlackRock
Baillie Gifford & Co
Swedbank AB
Adage Capital Partners GP
Vanguard Group
State Street Corporation
Geode Capital Management
Caledonia
Victory Capital Management
Northern Trust
Jane Street
Arrowstreet Capital, Limited Partnership

View all funds holding Royalty Pharma